oral pan-TEAD auto-palmitoylation inhibitor

tumor regression at 3 mg/kg QD

from 160k compound cell-based HTS

Mol. Cancer. Ther., Apr. 13, 2021

Vivace Therapeutics, San Mateo, CA


The Vivace Therapeutics pan-TEAD transcription factor inhibitor, VT-104, binds to a lipid pocket on TEAD, preventing its auto-palmitoylation, similar to a previously highlighted TEAD inhibitor. In contrast to previously published TEAD…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: